As previously reported, Cantor Fitzgerald initiated coverage of Eli Lilly (LLY) with an Overweight rating and $975 price target Lilly is off to “a solid start” in 2025, highlighted by positive orforglipron ACHIEVE-1 data and improved underlying GLP-1 commercial metrics, while Mounjaro momentum “continues unabated” and is nearing Ozempic levels, the analyst tells investors. The firm thinks Lilly could have 85%-plus share of the obesity market by 2029-2030 when the next wave of entrants hit, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly selloff on Novo report more than warranted, says Citi
- Eli Lilly & Co: Strong Growth Potential in GLP-1 Obesity Market with Positive Financial Outlook
- Eli Lilly initiated with an Overweight at Cantor Fitzgerald
- Novo submits obesity pill for FDA approval, BioPharma Dive reports
- Eli Lilly & Co: Strong Market Position and Growth Potential with Orforglipron Launch